NZ220612A - 11 residue influenza virus peptide and vaccines - Google Patents

11 residue influenza virus peptide and vaccines

Info

Publication number
NZ220612A
NZ220612A NZ220612A NZ22061283A NZ220612A NZ 220612 A NZ220612 A NZ 220612A NZ 220612 A NZ220612 A NZ 220612A NZ 22061283 A NZ22061283 A NZ 22061283A NZ 220612 A NZ220612 A NZ 220612A
Authority
NZ
New Zealand
Prior art keywords
vaccines
residue
influenza virus
virus peptide
peptide
Prior art date
Application number
NZ220612A
Other languages
English (en)
Inventor
N Green
S Alexander
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of NZ220612A publication Critical patent/NZ220612A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ220612A 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines NZ220612A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41045582A 1982-08-23 1982-08-23

Publications (1)

Publication Number Publication Date
NZ220612A true NZ220612A (en) 1988-07-28

Family

ID=23624803

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ220612A NZ220612A (en) 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines

Country Status (16)

Country Link
EP (1) EP0116629A4 (https=)
JP (1) JPS59501714A (https=)
KR (1) KR840006198A (https=)
AU (1) AU570929B2 (https=)
DK (1) DK203684A (https=)
ES (1) ES8505819A1 (https=)
FI (1) FI841583A0 (https=)
GR (1) GR78931B (https=)
IL (1) IL69556A (https=)
IT (1) IT1168636B (https=)
NO (1) NO161002C (https=)
NZ (2) NZ220612A (https=)
PH (1) PH18872A (https=)
PT (1) PT77230B (https=)
WO (1) WO1984000687A1 (https=)
ZA (1) ZA836080B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR241713A1 (es) * 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
WO1990008161A1 (en) * 1989-01-12 1990-07-26 The Blood Center Of Southeastern Wisconsin Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses
EP0621339B1 (en) * 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
EP2450377A1 (en) * 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
JP2011516423A (ja) 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
IT1395961B1 (it) * 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2536425B1 (en) * 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI83662C (fi) * 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.

Also Published As

Publication number Publication date
KR840006198A (ko) 1984-11-22
NZ205341A (en) 1988-07-28
ZA836080B (en) 1984-04-25
FI841583L (fi) 1984-04-19
AU570929B2 (en) 1988-03-31
NO161002B (no) 1989-03-13
FI841583A7 (fi) 1984-04-19
PT77230A (en) 1983-09-01
IT1168636B (it) 1987-05-20
IL69556A (en) 1988-05-31
FI841583A0 (fi) 1984-04-19
EP0116629A4 (en) 1987-06-29
NO161002C (no) 1989-06-21
PT77230B (en) 1986-02-04
AU1947183A (en) 1984-03-07
IT8348868A1 (it) 1985-02-22
IT8348868A0 (it) 1983-08-22
ES525088A0 (es) 1985-06-16
EP0116629A1 (en) 1984-08-29
IL69556A0 (en) 1983-11-30
PH18872A (en) 1985-10-21
JPS59501714A (ja) 1984-10-11
ES8505819A1 (es) 1985-06-16
NO841540L (no) 1984-04-17
GR78931B (https=) 1984-10-02
DK203684D0 (da) 1984-04-18
WO1984000687A1 (en) 1984-03-01
DK203684A (da) 1984-04-18

Similar Documents

Publication Publication Date Title
NZ205341A (en) 37 residue influenza virus peptide and vaccines
GB2181435B (en) Recombinant lav/htlv virus and vaccines
PH19997A (en) 20-bpiroxanes and analogues having an open ring e and pharmaceutical preparations thereof
IL61904A (en) Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
NZ220365A (en) Antiviral peptides and pharmaceutical compositions
GB2212511B (en) Hepatitis c virus
IL80895A0 (en) Material and methods for herpes simplex virus vaccination and diagnosis based on gd-2 glycoprotein
IL64847A (en) Immunomodulating phosphorylsubstituted muramylpeptide analogues and pharmaceutical compositions containing them
AU1255383A (en) Foot and mouth disease viral antigenic peptides
ZA864879B (en) Vaccines and diagnostics derived from boving diarrhoea virus
EP0210931A3 (en) Vaccine against varicella-zoster virus
GB2130090B (en) Pharmaceutical preparations and compositions
NZ221374A (en) Recombinant interferon and compositions containing it
IL101639A0 (en) Recombinant influenza vaccines
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
IL89118A0 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
GB8918689D0 (en) 25/15 vaccine
IL79740A0 (en) Hepatitis vaccine
ZA903142B (en) Canine corona virus vaccine
ZA866582B (en) Recombinant virus
NZ220611A (en) 30 residue influenza virus peptide, vaccines and antibodies
GB8615068D0 (en) Vaccines
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
ZA837058B (en) Peptide and use thereof